ASH 2022 | The potential of daratumumab alone or with CyBorD in patients with stage IV AL amyloidosis
Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, comments on the results of two studies that evaluated the safety and efficacy of single-agent daratumumab or daratumumab with CyBorD (cyclophosphamide, bortezomib, and dexamethasone) in patients with stage IV light chain (AL) amyloidosis. The two studies reported very promising results, with good tolerability and encouraging responses. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen: Honoraria, Other: Travel Support; Attralus: Honoraria; Takeda: Other: Travel Support; Alexion: Honoraria, Other: Travel Support; GSK: Honoraria.
